A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06394622
• Other study ID #: CGC729-IIT-02
• Status: Recruiting
• Phase: Phase 1
• Start date: April 11, 2024
• Est. completion date: June 28, 2026

Study information

• Verified date: April 2024
• Source: Fudan University
• Contact: Jian Zhang
• Phone: 18017312991
• Email: syner2000[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC729 in the treatment of advanced malignant solid tumors. Condition or disease:advanced malignant solid tumors. Intervention/treatment:Biological: CD70 CAR-NKT cells. Phase:I

Description:

This was a dose-expansion study, we plan to enroll 6 to 12 patients with CD70-positive advanced malignant solid tumors to CGC729 treatment. The intended enrollment for the evaluation of treatment efficacy and safety was planned to be 3 to 6 patients per tumor type. We used leukapheresis for cell collection. The lymphodepletion procedure was conducted using a combination of fludarabine and cyclophosphamide.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: June 28, 2026
• Est. primary completion date: June 28, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 18 to 75 years.
• ECOG 0-1 points.
• The expected survival time is more than 3 months.
• Patients with advanced advanced malignant solid tumor confirmed by histology or cytology to be recurrent or metastatic after at least second-line treatment.
• IHC: CD70 positive.
• At least one measurable lesion at baseline per RECIST version 1.1.
• The functions of important organs are basically normal:Hematopoietic function:

neutrophils 1.5×109/L, platelets 75×109/L, hemoglobin 80g/L;Renal function: creatinine clearance of =60 mL/min.;Liver function: ALT and AST =2.5×ULN (=5 × ULN for patients with liver metastases);Total bilirubin =1.5×ULN.Prothrombin time (PT) : INR < 1.7.

• Pregnancy tests for women of childbearing age shall be negative, Both men and women agreed to use effective contraception.
• Subjects or their guardians agree to participate in this clinical trial and sign the ICF, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the research.

Exclusion Criteria:

• Use of cell therapy within the previous one month.
• Risk of severe bleeding in esophageal cancer
• Subjects with other malignant tumors within the past 2 years, except basal or squamous skin cancer, superficial bladder cancer, and breast cancer in situ, have been completely cured and do not need follow-up treatment.
• Patients with leptomeningeal metastasis or central nervous system metastasis, and definite central nervous system underlying diseases with significant symptoms in the past 6 months.
• Immunotherapy, targeted drug therapy or chemotherapy within 5 drug half-lives within 2 weeks before cell infusion.
• Active hepatitis B, HIV positive and HCV positive
• Active infection or uncontrollable infection.
• Subjects with NYHA heart failure class =2 or hypertension uncontrolled by standard therapy requiring special treatment, previous history of myocarditis, or myocardial infarction within 6 months.
• Unstable respiratory diseases, including interstitial pneumonia.
• Uncontrolled ascites and pleural effusion
• Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, etc. .
• Subjects who are using systemic steroids or steroid inhalers for treatment.
• Pregnant or lactating female subjects.
• Other investigators deem it unsuitable to participate in the study.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Combination Product:
• Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells
Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.

Locations

Country	Name	City	State
China	Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR of CD70 CAR-NKT cell dynamics	Assess Objective response rate	Day 1 through week 56
Secondary	DCR of CD70 CAR-NKT cell dynamics	Disease control rate	Day 1 through week 56
Secondary	DOR of CD70 CAR-NKT cell dynamics	Duration of Response	Day 1 through week 56
Secondary	PFS of CD70 CAR-NKT cell dynamics	Progress Free Survival	Day 1 through week 56
Secondary	OS of CD70 CAR-NKT cell dynamics	Overall survival	Day 1 through week 56